Latozinemab

• CAT Number: I041389
• Purity: ≥95%

Latozinemab (Cat No.: I041389) is an investigational monoclonal antibody designed to target and inhibit sortilin, a protein implicated in neurodegenerative diseases like frontotemporal dementia (FTD) and Alzheimer’s disease. By blocking sortilin, latozinemab aims to increase levels of progranulin, a neuroprotective protein often deficient in FTD patients with GRN gene mutations. Preclinical studies have shown its potential to restore progranulin levels and reduce neuroinflammation. Currently in clinical trials, latozinemab represents a promising therapeutic approach for modifying disease progression in certain neurodegenerative conditions.

Reference

[1]. Sam Jackson, et al. Six months interim analysis of the phase 2 study of AL001 in frontotemporal dementia patients carrying a granulin mutation. Alzheimer’s & DementiaVolume 17: Drug Development.

[2]. Robert Paul, et al. AL001 Blocks the Sortilin/PGRN Interaction and is a Potential Therapy for FTD-GRN (4422). Neurology, April 13, 2021; 96 (15 Supplement).